BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26322428)

  • 1. Laser Therapy Versus Anti-VEGF Agents for Treatment of Retinopathy of Prematurity.
    Leskov I; Mukai S
    Int Ophthalmol Clin; 2015; 55(4):81-90. PubMed ID: 26322428
    [No Abstract]   [Full Text] [Related]  

  • 2. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.
    Hartnett ME
    Clin Perinatol; 2014 Dec; 41(4):925-43. PubMed ID: 25459781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab for retinopathy of prematurity.
    Gilbert CE; Zin A; Darlow B
    N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab for retinopathy of prematurity.
    Lim LS; Mitchell P; Wong TY
    N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
    [No Abstract]   [Full Text] [Related]  

  • 5. [Laser treatment or intravitreal VEGF inhibition for aggressive posterior retinopathy of prematurity?].
    Barth T; Hufendiek K; Helbig H; Oberacher-Velten I
    Ophthalmologe; 2015 Jun; 112(6):520-4. PubMed ID: 25573085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antivascular endothelial growth factor in the treatment of retinopathy of prematurity.
    Patel JR; Ranjan SS; Wasserman BN
    Curr Opin Ophthalmol; 2016 Sep; 27(5):387-92. PubMed ID: 27206263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
    Erol N; Gürsoy H; Sahin A; Basmak H
    J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.
    Moran S; O'Keefe M; Hartnett C; Lanigan B; Murphy J; Donoghue V
    Acta Ophthalmol; 2014 Sep; 92(6):e496-7. PubMed ID: 24428792
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent.
    Mireskandari K; Collins ME; Tehrani N
    Can J Ophthalmol; 2015 Dec; 50(6):409-12. PubMed ID: 26651298
    [No Abstract]   [Full Text] [Related]  

  • 10. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future trends in treatment of severe retinopathy of prematurity.
    Wallace DK; Wu KY
    Clin Perinatol; 2013 Jun; 40(2):297-310. PubMed ID: 23719311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review.
    Abri Aghdam K; Khadamy J; Falavarjani KG; Tsui I
    J AAPOS; 2016 Dec; 20(6):539-540.e3. PubMed ID: 27810419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION.
    Hong YR; Kim YH; Kim SY; Nam GY; Cheon HJ; Lee SJ
    Retina; 2015 Sep; 35(9):1772-7. PubMed ID: 25829347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Recurrent Retinopathy of Prematurity Following Anti-VEGF Injection.
    Bhatt AR; Paul Chan RV; Reynolds JD; Wagner RS
    J Pediatr Ophthalmol Strabismus; 2019 Mar; 56(2):68-70. PubMed ID: 30889257
    [No Abstract]   [Full Text] [Related]  

  • 16. Commentary: Are we there yet? Role of anti-vascular endothelial growth factor and laser in the management of retinopathy of prematurity.
    Sindal MD; Yadav D
    Indian J Ophthalmol; 2021 Aug; 69(8):2176-2177. PubMed ID: 34304204
    [No Abstract]   [Full Text] [Related]  

  • 17. Retinopathy of prematurity.
    Asano MK; Dray PB
    Dis Mon; 2014 Jun; 60(6):282-91. PubMed ID: 24906674
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-Vascular Endothelial Growth Factor Therapy in Pregnancy: What We Know, What We Don't Know, and What We Don't Know We Don't Know.
    Peracha ZH; Rosenfeld PJ
    Retina; 2016 Aug; 36(8):1413-7. PubMed ID: 27388726
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case report.
    Flavahan PW; Lavy TE; Wykes W
    Scott Med J; 2013 Aug; 58(3):130-2. PubMed ID: 23960050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New therapeutic approaches in the treatment of retinopathy of prematurity].
    Jandeck C
    Klin Monbl Augenheilkd; 2009 Nov; 226(11):914-20. PubMed ID: 19798624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.